Your Advisors
Michael A. Robinson
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance, and Nexus-9 Network.
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance, and Nexus-9 Network.
Michael'S LATEST HEADLINES
-
This Week's Top E-Commerce Stock Already Beat Amazon.com 10x Over - and It's About to Triple Again
Amazon's had a great five-year run, tacking on 405% in profits.
But there's an Amazon "backdoor" that costs far less than half the price of Amazon and that's returned 10X the money over those five years.
Now Michael Robinson thinks the stock has, conservatively, at least another 300% in gains still to come.
Read more... - This Stock Is the Best Way to Play the Biggest IPO Summer Ever
- Here's the Easiest Way to Cash In on the NFT Boom
- This $39 Tech Stock Opens a $304 Billion Opportunity
- Wall Street Is Wrong (Again) About This 69% Winner
- How to Easily Cash In on the Best IPOs
- This Is the Perfect ETF for 300% Growth… and Wall Street Is Sleeping on It
- This COVID-19 Vaccine Stock Has More Upside Than Pfizer or Moderna
- Silicon Valley's "Top Cop" Tech Stock Could Pay 20% Profits for Starters
- Zillow Stock Is the Key to America’s $1.9 Trillion Housing Boom